smartbax announces a EUR4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection models Progressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel mode of action against multi-drug resistant Gram-negative and Gram-positive bacteria Funding round led by Anobis Asset and Bayern Kapital; second closing remains open Munich, Germany, Oct. 22, […]